Information  X 
Enter a valid email address

Shield Therapeutics (STX)

  Print   

Friday 07 January, 2022

Shield Therapeutics

Investor Presentation

RNS Number : 7082X
Shield Therapeutics PLC
07 January 2022
 

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

 

Investor Presentation

 

H.C. Wainwright BIOCONNECT Virtual Conference

 

London, UK, 7 January, 2022:  Shield Therapeutics plc (LSE: STX), a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), announces that Greg Madison, Chief Executive Officer of Shield, is scheduled to present virtually at the H.C. Wainwright BIOCONNECT Virtual Conference on 10 January, 2022. Please see presentation details below:

 

Date/Time:   Virtual presentation available on-demand on Monday, 10 January, 2022 at 7:00 a.m. ET

Presenter:  Greg Madison, Chief Executive Officer

 

To access the virtual presentation, sign up for 1x1 meetings, or for more information about the H.C. Wainwright BIOCONNECT Virtual Conference, please refer to the conference website at www.hcwevents.com/bioconnect/.

 

For further information please contact:

 

Shield Therapeutics plc

www.shieldtherapeutics.com

Greg Madison, CEO

+44 (0) 191 511 8500

Hans-Peter Rudolf, CFO


 

Nominated Adviser and Joint Broker


Peel Hunt LLP


James Steel/Christopher Golden

+44 (0)20 7418 8900

 

Joint Broker

finnCap Ltd 

Geoff Nash/Alice Lane/George Dollemore 

 

 

 

+44 (0)20 7220 0500



Financial PR & IR Advisor


Walbrook PR (UK Advisor)


Paul McManus/Lianne Applegarth/Alice Woodings

 

Investor Contact (US Advisor)

+44 (0)20 7933 8780 or  [email protected]

LifeSci Advisors, LLC

John Mullaly

 

 

+1 617 429 3548 or [email protected]

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

 

Shield's proprietary lead product, Accrufer®/Feraccru®, has been approved for use in the United States, European Union, UK, Switzerland, and Australia. The product has patent coverage until the mid-2030s. The Company recently launched Accrufer ® in the US. Feraccru® is being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Accrufer®/Feraccru® in China, Hong Kong, Macau, and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.

 

For more information, please visit  www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUNURRUSUARUR

a d v e r t i s e m e n t